OS

Positive Results for Xtandi in the Pre-Chemotherapy Space

It was announced today that after observing significant benefits in overall survival (OS) and radiographic progression free survival (PFS) ,the two co-primary endpoints of the the Xtandi pre-chemotherapy trial, the Independent Data Monitoring Committee (IDMC) for The Phase 3 PREVAIL trial of enzalutamide in metastatic prostate cancer recommends that "the study be stopped and patients [...]

By Malecare|2017-10-19T10:49:22-04:00October 22nd, 2013|Advanced Prostate Cancer, Drugs & Treatments, Early/Expanded Access Programs, enzalutamide, Enzalutamide (MDV-3100), Fail First Therapy, General Information, Provenge, step therapy, Uncategorized, Understanding APC, Xtandi, Zytiga|1 Comment

Metastasis-Free Survival Is A Possible Biomarker for Overall Survival

Researchers at Johns Hopkins has concluded that metastasis-free survival appeared to independently predictor of overall survival (OS) in men with recurrent prostate cancer who underwent androgen deprivation therapy (ADT) after developing metastases. Men with biochemically recurrent prostate cancer (PSA only) tend to survive for long periods so the FDA gold standard for clinical trial endpoint [...]

By Malecare|2020-02-04T11:49:50-05:00September 4th, 2013|Advanced Prostate Cancer, Bio Chemical Recurrence, biomarkers, bisphosphonates, Clinical Trials, Clinical Trials, Drugs & Treatments, enzalutamide, Hormone Therapy, Research, Start A Cure, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments

Previous 34